HomeInsightsPE

Supriya Lifescience Ltd P/E Ratio

Supriya Lifescience Ltd P/E Ratio

download
stocks purchased

₹ 0.8 Cr

Volume transacted

stocks purchased

21.3 K

stocks traded

Last Updated time: 25 Jul 15:30 PM

Image

Supriya Lifescience Ltd

NSE: SUPRIYA

PE

25.8

Last updated : 25 Jul 15:30 PM

Key Highlights

    The P/E Ratio of Supriya Lifescience Ltd is 25.8 as of 25 Jul 15:30 PM .a1#The P/E Ratio of Supriya Lifescience Ltd changed from 26.1 on March 2019 to 17.1 on March 2023 . This represents a CAGR of -19.06% over 2 years. a1#The Latest Trading Price of Supriya Lifescience Ltd is ₹ 382.1 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.3 in 5 years. This represents a CAGR of -0.72%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.5. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Supriya Lifescience Ltd changed from ₹ 3967 crore on March 2019 to ₹ 1534 crore on March 2023 . This represents a CAGR of -37.80% over 2 years. a1#The Revenue of Supriya Lifescience Ltd changed from ₹ 103.71 crore to ₹ 160.37 crore over 8 quarters. This represents a CAGR of 24.35% a1#The EBITDA of Supriya Lifescience Ltd changed from ₹ 33.6 crore to ₹ 57.69 crore over 8 quarters. This represents a CAGR of 31.03% a1#The Net Pr of Supriya Lifescience Ltd changed from ₹ 25.25 crore to ₹ 36.93 crore over 8 quarters. This represents a CAGR of 20.94% a1#The Dividend Payout of Supriya Lifescience Ltd changed from 19.96 % on March 2019 to 5.38 % on March 2023 . This represents a CAGR of -27.95% over 4 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Supriya Lifescience Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Supriya Lifescience Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '2226.1
Mar '2317.1

Company Fundamentals for Supriya Lifescience Ltd

Market Cap

3,075 Cr

EPS

14.8

P/E Ratio (TTM) *

25.8

P/B Ratio (TTM) *

3.8

Day’s High

384.85

Day’s Low

380.0

DTE *

0.0

ROE *

14.6

52 Week High

424.8

52 Week Low

235.0

ROCE *

20.4

* All values are consolidated

Last Updated time: 25 Jul 15:30 PM

* All values are consolidated

Last Updated time: 25 Jul 15:30 PM

Image

Supriya Lifescience Ltd

NSE: SUPRIYA

PRICE

382.1

-2.45 (-0.64%)

stock direction

Last updated : 25 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Supriya Lifescience Ltd

Strength

0

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

Asset Value vs Market Value of Supriya Lifescience Ltd

Market Value

3,075

Asset Value

468

5.6 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Supriya Lifescience Ltd253,075
Sun Pharmaceuticals Industries Ltd40399,537
Zydus Lifesciences Ltd31121,312
Cipla Ltd28121,120
Divis Laboratories Ltd75120,782
Dr Reddys Laboratories Ltd20114,348

Key Valuation Metric of Supriya Lifescience Ltd

Earnings

119 Cr

25.8 X

PE Ratio

Market Cap

₹3075Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

119 Cr

25.8 X

PE Ratio

Market Cap

₹3075Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Supriya Lifescience Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Supriya Lifescience Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '223967
Mar '231535

* All values are a in crore

×

Historical Revenue of Supriya Lifescience Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Supriya Lifescience Ltd

Period
Jun '22104
Sep '22115
Dec '22108
Mar '23144
Jun '23135
Sep '23143
Dec '23143
Mar '24160

* All values are a in crore

×

Historical EBITDA of Supriya Lifescience Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Supriya Lifescience Ltd

Period
Jun '2234
Sep '2231
Dec '2217
Mar '2357
Jun '2347
Sep '2334
Dec '2345
Mar '2458

* All values are a in crore

×

Historical Net Profit of Supriya Lifescience Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Supriya Lifescience Ltd

Period
Jun '2225
Sep '2217
Dec '2210
Mar '2338
Jun '2329
Sep '2324
Dec '2330
Mar '2437

* All values are a in crore

×

Historical Dividend Payout of Supriya Lifescience Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Supriya Lifescience Ltd

Period
Mar '190
Mar '2020
Mar '213
Mar '223
Mar '235

* All values are a in %

About Supriya Lifescience Ltd

About Supriya Lifescience Ltd

    The company was incorporated as Supriya Lifescience Limited on 26 March 2008 upon the conversion of M/s Supriya Chemicals,a partnership firm, into a public limited company.The company commenced operations on 01 April 2008.The company is engaged in manufacturing and export of active pharmaceutical ingredients(APIs).The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. As of 31 March 2021,the company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively,of the API exports from India, between Fiscal 2017 and 2020.The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The company's products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company's business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra. The manufacturing facility is spread across 23,806 sq.mts, having reactor capacity of 332 KL per day.The company presently operate five cleanrooms and are setting up two new clean rooms that are expected to be commercialised in the first quarter of Fiscal 2022. The new clean rooms will add manufacturing capacity of 215 KL per day. On 31 March 2012,the company has issued and allotted 3002400 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 12:1. On 31 March 2013,the company has issued and allotted 1626302 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 1:2. On 01 October 2015,the company has issued and allotted 9757804 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 2:1 On 26 December 2020,the company has sub-divided its face value of equity shares from Rs 10 each to Rs 2 each. During the month of December 2021,the company came out with an Rs 700-crore public issue which comprised of a fresh issue of Rs 200 crore and an offer for sale(OFS) of Rs 500 crore by the promoter Satish Waman Wagh.The IPO shares were allotted at the price of Rs 274 per share including a premium of Rs 272 per share.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India Ltd(NSE) on 28 December 2021.

Supriya Lifescience Ltd News Hub

News

Board of Supriya Lifesciences recommends final dividend

Supriya Lifesciences announced that the Board of Directors of the Company at its meeting h...

Read more

29 May 202411:23

News

Supriya Lifesciences announces board meeting date

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 28 Ma...

Read more

22 May 202412:40

News

Supriya Lifesciences to discuss results

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 7 Feb...

Read more

01 Feb 202413:51

News

Supriya Lifesciences to conduct board meeting

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 7 Nov...

Read more

30 Oct 202317:29

News

Supriya Lifesciences to hold AGM

Supriya Lifesciences announced that the 15th Annual General Meeting (AGM) of the company w...

Read more

07 Sep 202311:03

News

Supriya Lifesciences to table results

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 3 Aug...

Read more

28 Jul 202312:54

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for PE of Supriya Lifescience Ltd

What is Supriya Lifescience Ltd current share price?

The current market price of Supriya Lifescience Ltd as of July 25, 2024 is ₹382.10.

What is Supriya Lifescience Ltd's market cap?

Supriya Lifescience Ltd's market capitalisation stood at ₹3,075 Cr as of July 25, 2024

What are Supriya Lifescience Ltd's total net assets?

According to Supriya Lifescience Ltd's most recent financial filings, the company's net assets total ₹468.1 Cr.

Is Supriya Lifescience Ltd making a profit or loss?

Supriya Lifescience Ltd's net Profit as of July 25, 2024 is close to ₹119 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199